FDA's ISTAND Pilot Program accepts a submission of first organ-on-a-chip technology designed to predict human drug-induced liver injury (DILI)
FDA accepts first letter of intent (LOI) into the ISTAND Pilot Program for an organ-on-a-chip techno...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
FDA accepts first letter of intent (LOI) into the ISTAND Pilot Program for an organ-on-a-chip techno...
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA Drug Approvals
Scope: Regulatory
Related coverage
More related coverage
Blaine Labs, Inc Issues Voluntary Nationwide Recall of Wound Care Gel Products Due to Microbial Contamination
Santa Fe Springs, California – April 07, 2026 – Blaine Labs, Inc. is voluntarily recalling three (3)...
Patient Listening Session Summaries
Patient Listening Session summaries are published after each session to share a high-level summary o...
FDA approves safety labeling changes for opioid pain medicines
Today, FDA is announcing final approval and immediately effective implementation of required labelin...
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain
FDA continues to investigate counterfeit Ozempic (semaglutide) injection 1 milligram (mg) in the leg...